Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix

Background and objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied time to castration and testosterone recovery in real-world patients with aPC unde...

Full description

Bibliographic Details

Published in:	Therapeutic Advances in Urology
Main Authors:	Patrick Campbell, Georges Gebrael, Arshit Narang, Chadi Hage Chehade, Vinay Mathew Thomas, Gliceida Galarza Fortuna, Nicolas Sayegh, Nishita Tripathi, Clara Tandar, Emre Dal, Haoran Li, Umang Swami, Neeraj Agarwal, Benjamin L. Maughan
Format:	Article
Language:	English
Published:	SAGE Publishing 2024-11-01
Online Access:	https://doi.org/10.1177/17562872241293779